FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab (BV) are considered standard 1st line treatment options for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of oxaliplatin-based chemotherapy combined with BV in patients with mCRC.

Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer

Cremolini, Chiara;Antoniotti, Carlotta;Falcone, Alfredo;
2020

Abstract

FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab (BV) are considered standard 1st line treatment options for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of oxaliplatin-based chemotherapy combined with BV in patients with mCRC.
Abraham, Jim P; Magee, Daniel; Cremolini, Chiara; Antoniotti, Carlotta; Halbert, David D; Xiu, Joanne; Stafford, Phillip; Berry, Donald A; Oberley, Matthew J; Shields, Anthony F; Marshall, John L; Salem, Mohamed E; Falcone, Alfredo; Grothey, Axel; Hall, Michael J; Venook, Alan P; Lenz, Heinz-Josef; Helmstetter, Anthony; Korn, W Michael; Spetzler, David B
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/1062540
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact